Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of Single Rising Oral Doses of BI 10773 in Healthy Males
NCT02172170Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2007
- Primary completion
- Mar 2007
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing BI 10773 with Placebo (2 arms). Primary endpoints: Number of patients with adverse events up to 33 days, Number of patients with clinically significant changes in vital signs up to 12 days and 4 more. Started Jan 2007; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02172170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02172170.